PFIZER INC.

Pfizer's mRNA-based influenza vaccine demonstrated 34.5% greater effectiveness against influenza A compared to standard flu vaccines in a Phase 3 trial involving over 18,000 participants aged 18-64.

Pfizer has entered a non-exclusive license agreement with Nona Biosciences to access their proprietary HCAb platform for generating fully human heavy chain-only antibodies across multiple disease indications.

Pfizer India has launched Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, for acute migraine treatment in adults with insufficient response to triptans.

Medicxi successfully raised €500 million ($581 million) for its sixth fund, demonstrating strong investor confidence in its asset-centric investment approach.

Pfizer sold 54.7% of its stake in German partner BioNTech, retaining approximately 1.66 million shares valued at $163.5 million as of September 30.

Day One Biopharmaceuticals announced the acquisition of Mersana Therapeutics for $129 million upfront, with potential additional payments of $156 million tied to development milestones.

Ingenus Pharmaceuticals received FDA approval and launched Conjugated Estrogens Tablets, USP, marking the first generic equivalent to Premarin Tablets available in the United States.

XOMA Royalty Corporation reported robust financial performance in Q3 2025, receiving $43.9 million in royalties and milestones from partners in the first nine months of 2025, including $14.3 million in Q3 royalties.

Nurix Therapeutics appointed Roger Dansey, M.D., former Chief Development Officer and Chief Oncology Officer of Pfizer Oncology, to its board of directors.

The Centers for Medicare & Medicaid Services announced the GENEROUS Model, a voluntary pilot program launching in 2026 that will allow participating state Medicaid programs to purchase select drugs at prices aligned with those paid in other developed countries.